Navigation Links
New Target for Muscular Dystrophy Drug Therapy Discovered

Researchers at the University of Pennsylvania School of Medicine have discovered a new target for the muscular dystrophy drug therapy .

The researchers have found how the gene for utrophin-which codes for a protein very similar to dystrophin, the defective protein in Duchenne muscular dystrophy (DMD)-puts the brakes on its own expression in muscle cells.

The production of utrophin slows in foetal muscles soon after birth, following which dystrophin takes over as the primary muscle-associated protein. How this normal utrophin silencing occurs has been a mystery for long, according to the background information in an article published online in Molecular Biology of the Cell.

Dr. Tejvir S. Khurana, Associate Professor of Physiology and Member of the Pennsylvania Muscle Institute, says the removal of silencing by drug intervention may help increase utrophin expression, which in turn may substitute for dystrophin as a possible therapy for DMD.

Experiments on mice have now shown that utrophin silencing is applied by a protein called Ets-2 repressor factor (ERF) sitting on a small piece of the utrophin gene called the N-box.

"We demonstrated that ERF significantly reduces or represses the activity of utrophin's N-box in muscle cells of mice," says Dr. Tejvir S. Khurana, 7senior author of the study.

During the study, the researchers noted that ERF did not have any effect on utrophin silencing when the N-box was deleted from the utrophin gene. They also observed that utophin mRNA production increased when ERF was repressed.

"This approach of 'repressing the repressor' is medically relevant to treating muscular dystrophy in that we hope to one day be able to upregulate utrophin production," explains Dr. Khurana.

Since the gene sequence of utrophin is over 80 per cent identical to that of dystrophin, it may substitute for dystrophin in muscle cells, says resea rchers.

Dr. Khurana, however, wants to ensure first whether repressing ERF reduces muscle deterioration in mice or not.

"We have worked on this problem for a number of years, and our current findings are a logical incremental step in understanding how utrophin could become an effective tool for treating DMD," states Dr. Khurana.


'"/>




Related medicine news :

1. Target for obesity treatment
2. Gel Offers A More Targeted Approach
3. In Search Of A New Drug To Target Cholesterol
4. In Search Of A New Drug To Target Cholesterol
5. Target of diabetes type 1 identified
6. Gene Target For Tuberculosis Identified
7. New Vaccine Targeted At Effective Treatment Against Tuberculosis
8. Novel Technique For Targeting Small-Cell Lung Cancer
9. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
10. Doctors, Pharma Companies Targeted By CBI Raids
11. Research Targets treatment for dementia and brain injuries
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the top ... Living (SHSL) may not share those same worries thanks to a new bundled ... while holding the line on increasing their contributions, including premiums, deductibles and the portions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology: